DOCS insider: Timothy Cabral converts, exercises options and completes 10b5-1 sales
Rhea-AI Filing Summary
Insider transactions by Doximity director Timothy S. Cabral on 08/15/2025: Mr. Cabral converted 20,000 shares of Class B common stock into Class A shares and exercised 20,000 stock options with a $2.21 exercise price, resulting in 20,000 newly acquired Class A shares. He sold 16,200 Class A shares at a weighted-average price of approximately $63.682 and an additional 3,800 Class A shares at a weighted-average price of approximately $64.1889, under a Rule 10b5-1 trading plan adopted February 13, 2025. After these transactions he directly held 10,160 and 6,360 Class A shares as reported across sales; total Class B and exercised option conversions are noted as convertible to Class A.
Positive
- Sales were executed under a Rule 10b5-1 trading plan, indicating pre-established, compliant disposition of shares
- Options exercised at a low exercise price ($2.21), converting compensation into equity ownership
- Disclosure includes weighted-average sale price ranges, allowing price transparency for investors
Negative
- None.
Insights
TL;DR: Routine 10b5-1 sales and option exercise by a director; modest share sales at market prices, limited immediate governance impact.
The filing shows option exercise at a nominal exercise price and conversion of Class B to Class A shares, followed by sales executed under a pre-established Rule 10b5-1 plan. The sales volumes (20,000 total sold) and prices (~$63.16–$64.25 ranges) represent personal liquidity actions rather than corporate financing or dilutive events. No indication of special related-party transactions or unusual timing is present in the Form 4.
TL;DR: Transactions are standard insider activity under an approved trading plan; no governance red flags disclosed.
The report documents conversion rights of Class B to Class A shares and automatic conversion triggers, consistent with the issuer's charter. Sales occurred pursuant to an established 10b5-1 plan adopted February 13, 2025, and were handled by an attorney-in-fact signature, indicating routine administration. The filing does not show any restricted transfers or departures that would materially affect board composition or control.
FAQ
What did Doximity director Timothy S. Cabral do on 08/15/2025 (DOCS)?
Were the share sales by Timothy Cabral planned or immediate trades?
At what prices were the shares sold in the Form 4?
How many Class A shares did Cabral beneficially own after the transactions?
Who signed the Form 4 filing for Timothy Cabral?